- Home
- NRGV vs ESPR Comparison
NRGV vs ESPR Comparison
Compare NRGV & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- ESPR
- Stock Information
- Founded
- NRGV 2017
- ESPR 2008
- Country
- NRGV United States
- ESPR United States
- Employees
- NRGV N/A
- ESPR N/A
- Industry
- NRGV Industrial Machinery/Components
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- ESPR Health Care
- Exchange
- NRGV Nasdaq
- ESPR Nasdaq
- Market Cap
- NRGV 629.6M
- ESPR 660.1M
- IPO Year
- NRGV N/A
- ESPR 2013
- Fundamental
- Price
- NRGV $3.58
- ESPR $2.54
- Analyst Decision
- NRGV Buy
- ESPR Buy
- Analyst Count
- NRGV 3
- ESPR 6
- Target Price
- NRGV $1.83
- ESPR $6.50
- AVG Volume (30 Days)
- NRGV 2.7M
- ESPR 5.6M
- Earning Date
- NRGV 11-10-2025
- ESPR 11-06-2025
- Dividend Yield
- NRGV N/A
- ESPR N/A
- EPS Growth
- NRGV N/A
- ESPR N/A
- EPS
- NRGV N/A
- ESPR N/A
- Revenue
- NRGV $51,716,000.00
- ESPR $303,802,000.00
- Revenue This Year
- NRGV $314.68
- ESPR $18.83
- Revenue Next Year
- NRGV $38.97
- ESPR N/A
- P/E Ratio
- NRGV N/A
- ESPR N/A
- Revenue Growth
- NRGV N/A
- ESPR 2.83
- 52 Week Low
- NRGV $0.60
- ESPR $0.69
- 52 Week High
- NRGV $4.56
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- NRGV 56.05
- ESPR 43.47
- Support Level
- NRGV $3.15
- ESPR $2.80
- Resistance Level
- NRGV $3.71
- ESPR $2.99
- Average True Range (ATR)
- NRGV 0.33
- ESPR 0.18
- MACD
- NRGV -0.06
- ESPR -0.03
- Stochastic Oscillator
- NRGV 56.61
- ESPR 14.01
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.